Výsledky vyhledávání - "Sissela Broos"

Akademický článek

Allergen-Specific Immunotherapy Alters the Frequency, as well as the FcR and CLR Expression Profiles of Human Dendritic Cell Subsets.

Autor: Kristina Lundberg, Frida Rydnert, Sissela Broos, Morgan Andersson, Lennart Greiff, Malin Lindstedt

Publikováno v: PLoS ONE, Vol 11, Iss 2, p e0148838 (2016)

Allergen-specific immunotherapy (AIT) induces tolerance and shifts the Th2 response towards a regulatory T-cell profile. The underlying mechanisms are not fully understood, but dendritic cells (DC) play a vital role as key regulators of T-cell respon

Externí odkaz: https://doaj.org/article/df1cc89af02c4f1cb50daf5ef8a10ea5

Zobrazit plný text záznamu

Supplementary Tables from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity

Autor: Peter Ellmark, Thomas H. Tötterman, Malin Lindstedt, Per Norlén, Eva Dahlén, Christina Furebring, Niina Veitonmäki, Erika Fletcher, Sissela Broos, Sara M. Mangsbo

Supplementary Table 1. Selection strategy Supplementary Table 2. Kinetic parameters for ADC-1013 and B44 measured by Biacore Supplementary Table 3. In vitro potency (EC50) of ADC-1013 in DC and B cell assays Supplementary table 4. Phenotypic profilin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2804768385233f8099f93098c871c58d
https://doi.org/10.1158/1078-0432.22459886.v1

Zobrazit plný text záznamu

Data from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity

Autor: Peter Ellmark, Thomas H. Tötterman, Malin Lindstedt, Per Norlén, Eva Dahlén, Christina Furebring, Niina Veitonmäki, Erika Fletcher, Sissela Broos, Sara M. Mangsbo

Purpose: Local administration of immune-activating antibodies may increase the efficacy and reduce the immune-related adverse events associated with systemic immunotherapy of cancer. Here, we report the development and affinity maturation of a fully

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fd6e11c37ca63c54a2a274a63887800
https://doi.org/10.1158/1078-0432.c.6524333.v1

Zobrazit plný text záznamu

Supplementary Figure 3 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity

Autor: Peter Ellmark, Thomas H. Tötterman, Malin Lindstedt, Per Norlén, Eva Dahlén, Christina Furebring, Niina Veitonmäki, Erika Fletcher, Sissela Broos, Sara M. Mangsbo

Supplementary Figure 3. Anti-tumor effect on MB49 tumors. ADC-1013 generates a significant anti-tumor effect on CD40 negative MB49 cells in hCD40tg mice. Treatment with ADC-1013 or isotype control was performed on day 7 and 10 post tumor inoculation.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3452b53c78c750759d06b3ae34d25e1
https://doi.org/10.1158/1078-0432.22459901

Zobrazit plný text záznamu

Supplementary Figure 2 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity

Autor: Peter Ellmark, Thomas H. Tötterman, Malin Lindstedt, Per Norlén, Eva Dahlén, Christina Furebring, Niina Veitonmäki, Erika Fletcher, Sissela Broos, Sara M. Mangsbo

Supplementary Figure 2. Microphotographs from cryo sections showing representative images of A) Spleen, B) Liver and C) Brain (one slide representing data from one female and one male mice) from hCD40+ mice stained with an anti-human CD40 antibody or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::542a8b1c20d7cd6b01db3b74579a38c4
https://doi.org/10.1158/1078-0432.22459904.v1

Zobrazit plný text záznamu

Supplementary Figure 6 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity

Autor: Peter Ellmark, Thomas H. Tötterman, Malin Lindstedt, Per Norlén, Eva Dahlén, Christina Furebring, Niina Veitonmäki, Erika Fletcher, Sissela Broos, Sara M. Mangsbo

Supplementary Figure 6. Splenocytes from complete responders (CR) from ADC-1013 treatment of MB40 tumors were transplanted to naive mice. The receiving naïve mice were then challenged with MB49 tumors and the tumor volume followed over time until th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5660a3536345e5fd8d638b17cfbdf7ee
https://doi.org/10.1158/1078-0432.22459892

Zobrazit plný text záznamu

Supplementary Figure 4 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity

Autor: Peter Ellmark, Thomas H. Tötterman, Malin Lindstedt, Per Norlén, Eva Dahlén, Christina Furebring, Niina Veitonmäki, Erika Fletcher, Sissela Broos, Sara M. Mangsbo

Supplementary Figure 4. Anti-tumor effect on MB49 tumors. ADC-1013 generates a significant anti-tumor effect on CD40 negative MB49 cells in hCD40tg mice. Treatment with ADC-1013 or isotype control was performed on day 7 and 10 post tumor inoculation.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a7817295e8bf9530eba195b45ff9b8d
https://doi.org/10.1158/1078-0432.22459898

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání